A founder French-Canadian GBA mutation, p.W378G, as a cause for synucleinopathies and Gaucher disease
Objective: To examine and characterize founder GBA mutations in the French-Canadian (FC) population Background: GBA mutations are the most common genetic risk factors for Parkinson’s…Temporal evolution of biomarkers from healthy ageing, isolated REM sleep behavior to early Parkinson’s disease
Objective: To study the temporal evolution of biomarkers of various modalities in healthy ageing controls (HC), the prodromal condition of isolated REM sleep behavior disorder…GBA haploinsufficiency accelerated alpha synuclein pathology with altered lipid metabolism in a premotor model of Parkinson’s disease
Objective: To make Parkinson’s disease (PD) mice model and investigate the mechanism how glucocerebrosidase (gba) heterozygous mutations contribute to asyn pathology and development of PD.…Natural occurring antibodies reduce aggregation of α-synuclein
Objective: We tested naturally occurring antibodies (nAbs) against α-synuclein both in vitro as well as in HEK293T cells to determine binding, cell viability and capacity…Genetic knock-down of HDAC4 attenuates rotenone-induced abnormal expression of α-synuclein by affecting autophagic flux in SH-SY5Y Cells
Objective: To assess whether histone deacetylase 4 (HDAC4) is related to the abnormal expression of α-synuclein (α-syn) via the autophagy pathway. Background: The overexpression and…Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease
Objective: To develop small molecular weight compounds (SMEs) as disease-modifying agents, which are designed to arrest or even reverse the aggregation process of alpha-synuclein (aSyn)…Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways
Objective: We aim to describe the molecular pathways at the crossroad of etiology and susceptibility in PD, focusing on Rin, coded by the recently associated…Brain insulin resistance in Parkinson’s disease
Objective: To test the hypothesis that brain insulin resistance (i.e. decreased insulin/insulin like growth factor (IGF)-1 signaling) occurs in the substantia nigra pars compacta (SNc)…Normal “heart” in Parkinson’s disease: Is this a distinct clinical phenotype?
Objective: The aim of this study was to investigate whether non-motor manifestations of Parkinson’s disease (PD) differ between patients with normal and abnormal myocardial metaiodobenzylguanidine (MIBG)…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 15
- Next Page »